Stopping GLP-1 drugs can quickly erase cardiovascular benefits
Even brief interruption tied to change in risk of heart attack, stroke and death WashU Medicine researchers found that stopping GLP-1 drugs such as semaglutide and tirzepatide — even temporarily — elevates the risk of heart attack, stroke and death compared to staying on the medication continuously. Following a rapid increase in popularity of GLP-1